{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:03:28Z","timestamp":1792008208442,"version":"4.4.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.numecd.2024.07.019","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T16:10:23Z","timestamp":1722874223000},"page":"103702","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Metabolic dysfunction-associated steatotic liver disease: A pathophysiology and clinical framework to face the present and the future"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5621-1374","authenticated-orcid":false,"given":"Salvatore","family":"Corrao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5071-1466","authenticated-orcid":false,"given":"Walter","family":"Gran\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Scibetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Mirarchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Amodeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Falcone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiano","family":"Argano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2024.07.019_bib1","article-title":"Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States","author":"Gawrieh","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.numecd.2024.07.019_bib2","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.numecd.2024.07.019_bib3","series-title":"Liver, metabolic and atherosclerotic risks of patients with cryptogenic steatotic liver disease","author":"Wang","year":"2023"},{"issue":"6","key":"10.1016\/j.numecd.2024.07.019_bib4","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2024.07.019_bib5","doi-asserted-by":"crossref","DOI":"10.1111\/liv.15695","article-title":"Exploring the landscape of steatotic liver disease in the general US population","author":"Ciardullo","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.numecd.2024.07.019_bib6","article-title":"Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease","author":"Loomba","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.numecd.2024.07.019_bib7","article-title":"Prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in a middle-aged population with overweight and normal liver enzymes, and diagnostic accuracy of noninvasive proxies","author":"Son","year":"2024","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.numecd.2024.07.019_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1334227","article-title":"Editorial: interactions between NAFLD and cardiac conduction, structure and function: recent advances and treatments","volume":"14","author":"Argano","year":"2023","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.numecd.2024.07.019_bib9","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-023-02014-z","article-title":"Machine learning identification of risk factors for heart failure in patients with diabetes mellitus with metabolic dysfunction associated steatotic liver disease (MASLD): the silesia diabetes-heart project","author":"Nabrdalik","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.numecd.2024.07.019_bib10","article-title":"Metabolic dysfunction-associated steatotic liver disease in older adults is associated with frailty and social disadvantage","author":"Clayton-Chubb","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.numecd.2024.07.019_bib11","doi-asserted-by":"crossref","DOI":"10.4254\/wjh.v15.i12.1253","article-title":"From metabolic dysfunction-associated fatty liver disease to metabolic dysfunction-associated steatotic liver disease: controversy and consensus","author":"Chen","year":"2023","journal-title":"World J Hepatol"},{"key":"10.1016\/j.numecd.2024.07.019_bib12","series-title":"U.S. Adults and adolescents","article-title":"Much more than a name change: impact of the new steatotic liver disease nomenclature on clinical algorithms and disease classification","author":"Ma","year":"2023"},{"key":"10.1016\/j.numecd.2024.07.019_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11082108","article-title":"Steatotic liver disease: metabolic dysfunction, alcohol, or both?","author":"Staufer","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.numecd.2024.07.019_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics13233503","article-title":"An optimized strategy based on conventional ultrasound for diagnosing metabolic dysfunction-associated steatotic liver disease","author":"Feng","year":"2023","journal-title":"Diagnostics"},{"key":"10.1016\/j.numecd.2024.07.019_bib15","article-title":"Potential mechanisms involving in the pathogenesis of MASLD and targets for pharmacotherapy. Advancements in metabolic associated steatotic liver disease (MASLD) research: diagnostics, small molecule developments and future directions","author":"Patil","year":"2023","journal-title":"Hepatol Res"},{"key":"10.1016\/j.numecd.2024.07.019_bib16","article-title":"Obesity definition, diagnosis, bias, standard operating procedures (SOPs), and telehealth: an Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022","volume":"1","author":"Fitch","year":"2022","journal-title":"Obes Pillars"},{"issue":"1","key":"10.1016\/j.numecd.2024.07.019_bib17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1517\/14796678.1.1.39","article-title":"Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia","volume":"1","author":"Bays","year":"2005","journal-title":"Future Cardiol"},{"issue":"5","key":"10.1016\/j.numecd.2024.07.019_bib18","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11883-014-0409-1","article-title":"Ockham's razor, and resolution of the obesity paradox","volume":"16","author":"Adiposopathy","year":"2014","journal-title":"Curr Atherosclerosis Rep"},{"key":"10.1016\/j.numecd.2024.07.019_bib19","article-title":"Basal metabolism, body composition and physical activity with central obesity in adults","author":"Chen","year":"2022","journal-title":"Syst Rev"},{"key":"10.1016\/j.numecd.2024.07.019_bib20","article-title":"Liver involvement in individuals with obesity: a cross-sectional study from western India","author":"Shastri","year":"2023","journal-title":"J Assoc Phys India"},{"key":"10.1016\/j.numecd.2024.07.019_bib21","article-title":"Correlation between central obesity and liver function in young adults\u2014a cross-sectional study","author":"Alvin","year":"2022","journal-title":"J Health Allied Sci Nu"},{"key":"10.1016\/j.numecd.2024.07.019_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2017.06.003","article-title":"New trends on obesity and NAFLD in Asia","author":"Fan","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2024.07.019_bib23","article-title":"Adiponectin negatively correlates with alcoholic and non-alcoholic liver dysfunction: health check-up study of Japanese men","author":"Hamano","year":"2012","journal-title":"Hepatol Res"},{"issue":"1","key":"10.1016\/j.numecd.2024.07.019_bib24","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11739-014-1104-5","article-title":"Hypoadiponectinemia, cardiometabolic comorbidities and left ventricular hypertrophy","volume":"10","author":"Di Chiara","year":"2015","journal-title":"Intern Emerg Med"},{"issue":"1","key":"10.1016\/j.numecd.2024.07.019_bib25","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/AC.70.1.3064591","article-title":"Circulating adiponectin: a cardiometabolic marker associated with global cardiovascular risk","volume":"70","author":"Chiara","year":"2015","journal-title":"Acta Cardiol"},{"key":"10.1016\/j.numecd.2024.07.019_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/hep.20280","article-title":"Beyond insulin resistance in NASH: TNF-? Or adiponectin?","author":"Hui","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2024.07.019_bib27","doi-asserted-by":"crossref","DOI":"10.1172\/JCI200317797","article-title":"The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice","author":"Xu","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.numecd.2024.07.019_bib28","article-title":"Study of adiponectin promotor methylation status in patients with non alcoholic fatty liver disease","author":"El-moaty","year":"2021","journal-title":"Benha J Appl Sci"},{"key":"10.1016\/j.numecd.2024.07.019_bib29","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M209459200","article-title":"Serine phosphorylation of insulin receptor substrate 1 by inhibitor \u039aB kinase complex","author":"Gao","year":"2002","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.numecd.2024.07.019_bib30","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jhepr.2019.07.002","article-title":"From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options","volume":"1","author":"Gastaldelli","year":"2019","journal-title":"JHEP Rep"},{"issue":"2","key":"10.1016\/j.numecd.2024.07.019_bib31","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jhep.2022.09.020","article-title":"Mitochondrial alterations in fatty liver diseases","volume":"78","author":"Fromenty","year":"2023","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.numecd.2024.07.019_bib32","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.numecd.2024.07.019_bib33","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/MOL.0000000000000756","article-title":"Nonalcohol fatty liver disease: balancing supply and utilization of triglycerides","volume":"32","author":"Santos-Baez","year":"2021","journal-title":"Curr Opin Lipidol"},{"issue":"4","key":"10.1016\/j.numecd.2024.07.019_bib34","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2337\/dc15-1876","article-title":"Metabolic impact of nonalcoholic steatohepatitis in obese patients with type 2 diabetes","volume":"39","author":"Lomonaco","year":"2016","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.numecd.2024.07.019_bib35","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1111\/liv.15005","article-title":"PPAR-\u03b3-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH","volume":"41","author":"Gastaldelli","year":"2021","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.numecd.2024.07.019_bib36","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/hep.28985","article-title":"Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease","volume":"65","author":"Bril","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2024.07.019_bib37","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.84.10.3516","article-title":"Cloning and sequence analysis of cDNA for the canine neurotensin\/neuromedin N precursor","author":"Dobner","year":"1987","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.numecd.2024.07.019_bib38","doi-asserted-by":"crossref","DOI":"10.1159\/000199047","article-title":"Electrophysiological effects of neurotensin on globus pallidus neurons of 6-hydroxydopamine-lesioned rats","author":"Xue","year":"2009","journal-title":"Neurosignals"},{"key":"10.1016\/j.numecd.2024.07.019_bib39","doi-asserted-by":"crossref","DOI":"10.1097\/MED.0b013e3283419052","article-title":"The role of neurotensin in physiologic and pathologic processes","author":"Mustain","year":"2011","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.numecd.2024.07.019_bib40","article-title":"Neuropeptides exert neuroprotective effects in Alzheimer's disease","author":"Chen","year":"2019","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.numecd.2024.07.019_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/sj.ki.5002192","article-title":"Physiologic and pathophysiologic roles of lipid mediators in the kidney","author":"Hao","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.numecd.2024.07.019_bib42","doi-asserted-by":"crossref","DOI":"10.1194\/jlr.M500348-JLR200","article-title":"Aminophospholipid glycation and its inhibitor screening system: a new role of pyridoxal 5\u2032-phosphate as the inhibitor","author":"Higuchi","year":"2006","journal-title":"J Lipid Res"},{"key":"10.1016\/j.numecd.2024.07.019_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2023.116884","article-title":"AGEs accumulation with vascular complications, glycemic control and metabolic syndrome: a narrative review","volume":"176","author":"Pal","year":"2023","journal-title":"Bone"},{"issue":"11","key":"10.1016\/j.numecd.2024.07.019_bib44","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/s41551-023-01019-z","article-title":"Advanced glycation end-products as mediators of the aberrant crosslinking of extracellular matrix in scarred liver tissue","volume":"7","author":"Lyu","year":"2023","journal-title":"Nat Biomed Eng"},{"issue":"3","key":"10.1016\/j.numecd.2024.07.019_bib45","doi-asserted-by":"crossref","first-page":"748","DOI":"10.3390\/antiox12030748","article-title":"Involvement of intracellular TAGE and the TAGE\u2013RAGE\u2013ROS Axis in the onset and progression of NAFLD\/NASH","volume":"12","author":"Sakasai-Sakai","year":"2023","journal-title":"Antioxidants"},{"key":"10.1016\/j.numecd.2024.07.019_bib46","article-title":"Plasma advanced glycation end products are associated with incident cardiovascular events in individuals with type 2 diabetes: a case-cohort study with a median follow-up of 10 Years (EPIC-NL)","author":"J Hanssen","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.numecd.2024.07.019_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0251283","article-title":"Advanced glycation end products and cognitive impairment in schizophrenia","author":"Kobori","year":"2021","journal-title":"PLoS One"},{"issue":"19","key":"10.1016\/j.numecd.2024.07.019_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911689","article-title":"Current research on the pathogenesis of NAFLD\/NASH and the gut\u2013liver Axis: gut microbiota, dysbiosis, and leaky-gut syndrome","volume":"23","author":"Kobayashi","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.numecd.2024.07.019_bib49","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1111\/liv.14696","article-title":"Intestinal permeability in human nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"40","author":"De Munck","year":"2020","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.numecd.2024.07.019_bib50","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jhep.2008.03.007","article-title":"The gut\u2013liver-axis: endotoxemia, inflammation, insulin resistance and NASH","volume":"48","author":"Siebler","year":"2008","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.numecd.2024.07.019_bib51","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jcmgh.2015.01.001","article-title":"Hepatic injury in nonalcoholic steatohepatitis contributes to altered intestinal permeability","volume":"1","author":"Luther","year":"2015","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"15","key":"10.1016\/j.numecd.2024.07.019_bib52","doi-asserted-by":"crossref","first-page":"8309","DOI":"10.3390\/ijms22158309","article-title":"The gut microbiota-derived immune response in chronic liver disease","volume":"22","author":"Won","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.numecd.2024.07.019_bib53","doi-asserted-by":"crossref","first-page":"8096","DOI":"10.1038\/srep08096","article-title":"Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease","volume":"5","author":"Jiang","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.numecd.2024.07.019_bib54","first-page":"1","article-title":"Short-chain fatty acid: an updated review on signaling, metabolism, and therapeutic effects","author":"Rekha","year":"2022","journal-title":"Crit Rev Food Sci Nutr"},{"issue":"17","key":"10.1016\/j.numecd.2024.07.019_bib55","doi-asserted-by":"crossref","first-page":"6356","DOI":"10.3390\/ijms21176356","article-title":"Short-Chain fatty acids and their association with signalling pathways in inflammation, glucose and lipid metabolism","volume":"21","author":"He","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.numecd.2024.07.019_bib56","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/jgh.12556","article-title":"Gut microbiota and liver disease","volume":"29","author":"Goel","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.numecd.2024.07.019_bib57","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/hep.27490","article-title":"Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease","volume":"61","author":"Dongiovanni","year":"2015","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.numecd.2024.07.019_bib58","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/hep.24806","article-title":"Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents","volume":"55","author":"Santoro","year":"2012","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.numecd.2024.07.019_bib59","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1002\/hep.29064","article-title":"The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B","volume":"65","author":"Thabet","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2024.07.019_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102866","article-title":"MBOAT7 down-regulation by genetic and environmental factors predisposes to MAFLD","volume":"57","author":"Meroni","year":"2020","journal-title":"EBioMedicine"},{"issue":"17","key":"10.1016\/j.numecd.2024.07.019_bib61","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241713406","article-title":"Evaluation of human hepatocyte drug metabolism carrying high-risk or protection-associated liver disease genetic variants","volume":"24","author":"Faccioli","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.numecd.2024.07.019_bib62","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11102761","article-title":"Pathology and pathogenesis of metabolic dysfunction-associated steatotic liver disease-associated hepatic tumors","author":"Takahashi","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.numecd.2024.07.019_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15184566","article-title":"Recent insights into the biomarkers, molecular targets and mechanisms of non-alcoholic steatohepatitis-driven hepatocarcinogenesis","author":"Kakehashi","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.numecd.2024.07.019_bib64","article-title":"Facing the enigma of the vascular network in hepatocellular carcinomas in cirrhotic and non-cirrhotic livers","author":"Vasuri","year":"2015","journal-title":"J Clin Pathol"},{"issue":"9","key":"10.1016\/j.numecd.2024.07.019_bib65","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1007\/s10620-017-4654-3","article-title":"miRNA signature of hepatocellular carcinoma vascularization: how the controls can influence the signature","volume":"62","author":"Fittipaldi","year":"2017","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.numecd.2024.07.019_bib66","series-title":"The interplay of TGF-\u03b21 and cholesterol orchestrating hepatocyte cell fate, EMT, and signals for HSC activation","author":"Wang","year":"2023"},{"issue":"7","key":"10.1016\/j.numecd.2024.07.019_bib67","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.clnu.2024.05.042","article-title":"Inflammatory markers as diagnostic and precision nutrition tools for metabolic dysfunction-associated steatotic liver disease: results from the Fatty Liver in Obesity trial","volume":"43","author":"Mogna-Pel\u00e1ez","year":"2024","journal-title":"Clin Nutr"},{"issue":"7","key":"10.1016\/j.numecd.2024.07.019_bib68","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1017\/S1368980016003177","article-title":"Med Diet 4.0: the Mediterranean diet with four sustainable benefits","volume":"20","author":"Dernini","year":"2017","journal-title":"Publ Health Nutr"},{"issue":"2S3","key":"10.1016\/j.numecd.2024.07.019_bib69","first-page":"E36","article-title":"Modern vision of the Mediterranean diet","volume":"63","author":"Kiani","year":"2022","journal-title":"J Prev Med Hyg"},{"issue":"11","key":"10.1016\/j.numecd.2024.07.019_bib70","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/oby.23887","article-title":"Effects of short-term supervised exercise training on liver fat in adolescents with obesity: a randomized controlled trial","volume":"31","author":"Tas","year":"2023","journal-title":"Obesity"},{"issue":"1","key":"10.1016\/j.numecd.2024.07.019_bib71","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jhep.2012.02.023","article-title":"Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"57","author":"Keating","year":"2012","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.numecd.2024.07.019_bib72","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jhep.2016.08.023","article-title":"Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review","volume":"66","author":"Hashida","year":"2017","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.numecd.2024.07.019_bib73","first-page":"528","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol"},{"issue":"2","key":"10.1016\/j.numecd.2024.07.019_bib74","first-page":"185","article-title":"Efficacy of dietary intervention and physical activity in children and adolescents with nonalcoholic fatty liver disease associated with obesity: a scoping review","volume":"84","author":"Caro-Sabido","year":"2019","journal-title":"Rev Gastroenterol Mex Engl"},{"issue":"7","key":"10.1016\/j.numecd.2024.07.019_bib75","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0","article-title":"Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach","volume":"6","author":"Targher","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.numecd.2024.07.019_bib76","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.3390\/nu12103118","article-title":"Genomics in personalized nutrition: can you \u201ceat for your genes\u201d","volume":"12","author":"Mullins","year":"2020","journal-title":"Nutrients"},{"issue":"2","key":"10.1016\/j.numecd.2024.07.019_bib77","first-page":"637","article-title":"The future of hepatology","volume":"78","author":"Friedman","year":"2023","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.numecd.2024.07.019_bib78","article-title":"Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)","volume":"13","author":"Rong","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.numecd.2024.07.019_bib79","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction\u2013associated steatohepatitis with liver fibrosis","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.numecd.2024.07.019_bib80","article-title":"METTL3 drives NAFLD-related hepatocellular carcinoma and is a therapeutic target for boosting immunotherapy","volume":"4","author":"Pan","year":"2023","journal-title":"Cell Rep Med"},{"issue":"5","key":"10.1016\/j.numecd.2024.07.019_bib81","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3390\/jpm13050830","article-title":"Precision medicine in fatty liver disease\/non-alcoholic fatty liver disease","volume":"13","author":"Valenzuela-Vallejo","year":"2023","journal-title":"J Personalized Med"},{"issue":"3","key":"10.1016\/j.numecd.2024.07.019_bib82","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41591-023-02242-6","article-title":"Challenges and opportunities in NASH drug development","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.numecd.2024.07.019_bib83","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/hep.30626","article-title":"Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps","volume":"70","author":"Lonardo","year":"2019","journal-title":"Hepatol Baltim Md"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093947532400293X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093947532400293X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T07:12:42Z","timestamp":1738912362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S093947532400293X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":83,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S093947532400293X"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2024.07.019","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic dysfunction-associated steatotic liver disease: A pathophysiology and clinical framework to face the present and the future","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2024.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V. on behalf of The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University.","name":"copyright","label":"Copyright"}],"article-number":"103702"}}